All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma Hub is an independent medical education platform, sponsored by Roche, AbbVie, BeOne, Miltenyi Biomedicine, Thermo Fisher, Nurix Therapeutics and Caribou Biosciences and supported through independent educational grants from Incyte, Bristol Myers Squibb, Pfizer and Takeda Pharmaceuticals U.S.A., Inc. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View lymphoma & CLL content recommended for you
CALYM / IMAGINE Workshop 2018: Registration now open
Registration is now open for the CALYM / IMAGINE workshop which will take place on the 19th January 2018 in Paris, France. The workshop has been organized by the CALYM Carnot Institute and the IMAGINE Associated Carnot Institute to address the topic of “translating next generation genomics in precision medicine”.
A provisional program has been released that includes sessions on somatic and germline genetics, identification of therapeutic targets and biomarkers in lymphoma using new genomic technologies (Crispr/Cas9), and a round table discussion. The workshop aims to bring together academic and industrial specialists to discuss genetic advances in the innovation of therapies in lymphoma and immune deficiencies, and is co-chaired by Olivier Hermine (IMAGINE) and Gilles Salles (CALYM)
To register for the workshop visit the website here. Registration is open until 22nd December 2017.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.
Your opinion matters
When selecting the next therapy for patients with R/R MCL after BTKi progression, what is your most important consideration?